α-O-linked glycoconjugates, methods of preparation and...

Details α-O-linked glycoconjugates, methods of preparation and... α-O-linked glycoconjugates, methods of preparation and...

2007-01-09

2007-01-09

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S185100, C424S194100, C424S277100, C530S322000

Reexamination Certificate

active

10205021

ABSTRACT:
The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the α-O-linked glycoconjugates.

REFERENCES:
patent: 5053489 (1991-10-01), Kufe
patent: 5212298 (1993-05-01), Rademacher et al.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5280113 (1994-01-01), Rademacher et al.
patent: 5376531 (1994-12-01), Anderson et al.
patent: 5421733 (1995-06-01), Nudelman et al.
patent: 5491088 (1996-02-01), Hellstrom et al.
patent: 5625030 (1997-04-01), Williams et al.
patent: 5660834 (1997-08-01), Kjeldsen et al.
patent: 5679769 (1997-10-01), Danishefsky et al.
patent: 5683674 (1997-11-01), Taylor-Papadimitriou et al.
patent: 5747048 (1998-05-01), Kjeldsen et al.
patent: 5798090 (1998-08-01), Longenecker et al.
patent: 5807559 (1998-09-01), Jondal
patent: 5858994 (1999-01-01), Kretzschmar et al.
patent: 5871990 (1999-02-01), Clausen et al.
patent: 6013779 (2000-01-01), Wong et al.
patent: 6090789 (2000-07-01), Danishefsky et al.
patent: 6222020 (2001-04-01), Taylor-Papadimitriou et al.
patent: 6238668 (2001-05-01), Danishefsky et al.
patent: RE38046 (2003-03-01), Longenecker et al.
patent: 6660714 (2003-12-01), Danishefsky et al.
patent: 2002/0006900 (2002-01-01), Danishefsky et al.
patent: 2002/0038017 (2002-03-01), Danishefsky et al.
patent: 2003/0153492 (2003-08-01), Danishefsky et al.
patent: 2004/0102607 (2004-05-01), Danishefsky et al.
patent: 2004/0208884 (2004-10-01), Danishefsky et al.
patent: 2005/0222398 (2005-10-01), Danishefsky et al.
patent: 341252 (1997-11-01), None
patent: 8-319300 (1996-12-01), None
patent: WO 93/21948 (1993-11-01), None
patent: WO 96/34005 (1996-10-01), None
patent: WO 96/40198 (1996-12-01), None
patent: WO 97/03995 (1997-02-01), None
patent: WO 98/30190 (1998-07-01), None
patent: WO 98/46246 (1998-10-01), None
patent: WO 99/15201 (1999-04-01), None
patent: WO 99/48515 (1999-09-01), None
patent: WO 01/14395 (2001-03-01), None
patent: WO 01/14395 (2001-03-01), None
patent: WO 01/14395 (2001-03-01), None
U.S. Appl. No. 08/457,485, filed Jun. 1, 1995, Taylor-Papadimitriou, et al.
* Allen, et al., “A Second Generation Synthesis of the MBrl (Globo-H) Breast Tumor Antigen: New Application of the N-Pentenyl Glycoside Method for Achieving Complex Carbohydrate Protein Linkages”, Chem. Eur. J., 6(8): 1366-1375, 2000.
* Balcom. B.J. and Petersen, N.O., “Synthesis and Surfactant Behavior of an Unusual Cyclic Triester Based on acis, cis-1, 3, 5-Cyclohexanetriol Headgroup,”Langmuir, 7:2425-2427, 1991.
* Bayle, et al., “O-(3-Butenyl) A Stable Blocking Group Removable by Ozonolysis”,Carbohydrate Research, 232: 375-380, 1992.
* Bencomo et al.. “Synthesis of glycopeptides having clusters ofO-glycosylic disaccharide chains . . . ,”Carbohydrate Research, 116, C9-C12. 1983.
* Bilodeau M.T., “Total Synthesis of a Human Breast Tumor Associated Antigen”,J. Am. Chem. Soc., 117:7840-7841. 1995.
* Boehm T. et al., “Development of a Novel Silyl Ether Linker for Solid-Phase Organic Synthesis”J. Org. Chem., 61:6498-6499, 1996.
* Boon. T.. “Toward a Genetic Analysis of Tumor Rejection Antigens,”Adv. Can. Res., 58:177-211, 1992.
* Broddefalk, et al., “Preparation of a Glycopeptide Analogue of Type II Collagen—Use of Acid Labile Protective Groups for Carbohydrate Moieties in Solid Phase Synthesis of O-Linked Glycopeptides”,Tetrahedron Letters, NL, Elsevier Science, 37(17): 3011-3014, 1996.
* Cabaret. et al., “Amphiphilic Liposaccharides. Synthesis and Reductive Cleavage of C-Allyl, O-Allyl, and O-Butenyl Glycosyl Derivatives”.Carbohydrate Research. 189: 341-348, 1989.
* Chan et al., “Polymer-anchored Organosilyl Protecting Group in Organic Synthesis,”J. Chem. Soc., Chem. Commun., 909-911, 1985.
* Collins and Ferrier Monosaccharides: Their Chemistry and Their Roles in Natural Products, Publ. by John Wiley & Sons, Ltd., p. 4, 1995.
* Commissions on Nomenclature of Organic Chemistry and Physical Organic Chemistry. IUPAC,Pure and Applied Chemistry, 67, 1325 and 1334, 1995.
* Danishefsky et al. “Glycals in Organic Synthesis: The Evolution of Comprehensive Strategies for the Assembly of Oligosaccharides and Glycoconjugates of Biological Consequence”Angew. Chem. Int. Ed. Engl., 35:1380-1419, 1996.
* Danishefsky et al. “From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines”Angew. Chem. Int. Ed. Engl., 39:836-863, 2000.
* Dermer. G.B., “Another Anniversary for the War on Cancer,”Bio/Technology, 12, 320, 1994.
* Deshpande et al., “Strategy in Oligosaccharide Synthesis: An Application to a Concise Total Synthesis of the KH-1 (Adenocarcinoma) Antigen,”J. Am. Chem. Soc., 120, 1600-1614, 1998.
* Elofsson and Kihlberg, “Synthesis of Tn and Sialyl Tn Building Blocks for Solid Phase Glycopeptide Synthesis,”Tetrahedron Letters, 36, 7499-7502, 1995.
* Elofsson et al., “Preparation of Tn and Sialyl Tn Building Blocks . . . ,”Tetrahedron. 53, 369-390. 1997.
* Ezzell, “Cancer “Vaccines”: An Ideal Whose Time Has Come?” J. NIH Res, 7, 46-49, 1995.
* Finn et al., “MUC-1 Epithelial Tumor Mucin-based Immunity and Cancer Vaccines”Immunol. Rev., 145, 61-89, 1995.
* Freshney, R.I., Culture of Animal Cells, A Manual of Basic Techniques. Alan R. Liss, Inc., New York, p. 3-4, 1983.
* Fung et al., “Active Specific Immunotherapy of Murine Mammary . . . ,”Cancer Research. 50, 4308-4314. 1990.
* Garg et al., “Developments in the Synthesis of Glycopeptides Containing Glycosyl L-Asparagine, L-Serine, and L-Threonine”Adv. Carb. Chem. Biochem., 50, 277-310, 1994.
* Gleiter et al., “Synthesis and Properties of Eight-and Ten-Membered Selenaradialenes,”Tetrahedron Letters, 35, 8779-8782. 1994.
* Grice et al., “Tuning and Reactivity of Glycosides: Efficient One-pot Oligosaccharide Synthesis,”Synlett, 781-784. 1995.
* Iijima, II. and Ogawa, T. “Synthesis of Mucin-type O-Glycosylated Amino Acid β-Gal-(1-3)-[α-Neu5Ac-2→6)]-GalNAc-(1→3)-Ser”Carbohydr. Res., 186, 95-106, 1989.
* Kaizu et al., “Novel Fucolipids of Human Adenocarcinoma: Monoclonal Antibody Specific for Trifucosyl Ley(III3FucV3FucVI2FucnI.c6) and a Possible Three-dimensional Epitope Structure,”J. Biol. Chem. 261, 11254-11258. 1986.
* Kameyama et al., “Total Synthesis of Sialyl Lewis X*,”Carbohydrate Research, 209, cl-c4, 1991.
* Kim et al., “Expression of LeYand Extended LeYBlood Group-related Antigens in Human Malignant, Premalignant, and Nonmalignant Colonic Tissues,”Cancer Res., 46, 5985-5992, 1986.
* Koganty et al., “Glycopeptide- and Carbohydrate-based Synthetic Vaccines for the Immunotherapy of Cancer,”Drug Discovery Today, 5, 190-198, 1996.
* Kondo et al., “In vitroAction of Human and Porcineα-amylases . . .,” Carbohydrate Research, 204, 207-213, 1990.
* Kunz, H. and Birnbach, S., “Synthesis ofO-Glycopeitides of the Tumor-Associated TN. . .”Angew. Chem. Int. Ed. Engl., 25. 360-362, 1986.
* Lassaletta, et al., “Glycosyl Imidates. Synthesis of the Hexasaccharidc Moiety of Globo H (Human Breast Cancer) Antigen”, Liebigs Ann. 9: 1417-1423, 1996.
* Lay L. et al., “Oligosaccharides Related to Tumor-Associated Antigens”,Helv. Chim. Acta. 77:509-514, 1994.
* Liebe, B. and Kunz H., “Solid Phase Synthesis of a Tumor-Associated Sialyl-TNAntigen Glycopeptide- . . . ,”Angew. Chem. Int. Ed. Engl. 33. 618-621. 1997.
* Lönn. H. “Synthesis of a Tri- and a Hepta-saccharide . . . ,”Carb

Affiliated with

Also associated with

Rating

α-O-linked glycoconjugates, methods of preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with α-O-linked glycoconjugates, methods of preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α-O-linked glycoconjugates, methods of preparation and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3730839